Published: 1 December 2018
Author(s): Francesca Gay, Alessandra Larocca
Section: Invited Article

Multiple myeloma (MM) is a neoplastic disease typical of the elderly. Many steps forward have been made in the characterization of patients, and new treatment strategies are available today. Clinical trials represent a major point in the definition of standard treatment, although they usually include fit patients, while frail patients are commonly excluded. Therefore, frail patients may receive treatments that may be too toxic, thus jeopardizing the beneficial effects of therapy. A careful patient assessment is crucial to better characterize patients and consequently to appropriately select treatment.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.